ARZERRA Drug Profile

Summary for Tradename: ARZERRA

High Confidence Patents:	23
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ARZERRA

Recent Clinical Trials for ARZERRA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Henan Provincial People's Hospital	Phase 1/Phase 2
Tang-Du Hospital	Phase 1/Phase 2
TerSera Therapeutics	Phase 2

See all ARZERRA clinical trials

Pharmacology for ARZERRA

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ARZERRA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ARZERRA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326		2035-05-20	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326		2034-02-25	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326		2036-09-23	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326		2037-05-31	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326		2037-05-25	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326		2034-12-11	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ARZERRA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326		2036-12-20	Patent claims search
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326		2035-01-08	Patent claims search
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326		2034-02-07	Patent claims search
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326		2035-11-20	Patent claims search
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326		2035-07-16	Patent claims search
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326		2035-02-20	Patent claims search

International Patents for ARZERRA

Country	Patent Number	Estimated Expiration
European Patent Office	3359693
Poland	3821912
Hong Kong	129394
Australia	3059401
Japan	6435334
Cyprus	1793

ARZERRA (ofatumumab) Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

ARZERRA (ofatumumab) is a next-generation anti-CD20 monoclonal antibody with an established commercial footprint in chronic lymphocytic leukemia (CLL). Its market dynamics have been shaped by (1) competitive displacement from newer targeted CLL regimens, (2) payer and formulary pressure as efficacy and safety benchmarks shifted, and (3) a shrink in addressable patient segments as treatment sequencing changed toward Bruton tyrosine kinase (BTK) inhibitors and BCL2 inhibitors. Financial trajectory follows the same pattern: revenue growth did not sustain beyond early launch cycles, and the commercial base eroded as frontline and relapsed lines migrated to oral combination and single-agent targeted therapies.

Where does ARZERRA fit in the CLL treatment map?

ARZERRA is an anti-CD20 therapy used in CLL. Commercial relevance depends on how clinicians allocate patients across line of therapy and regimen class. Across the last decade of CLL care, the center of gravity shifted from immunochemotherapy to targeted oral drugs. The result is structural demand pressure on anti-CD20 antibodies, even where they retain a role in selected regimens.

Line-of-therapy pressure from targeted regimens

• Frontline displacement: BTK inhibitors and BCL2 pathway inhibitors moved into earlier lines, reducing eligible volumes for antibody-based chemoimmunotherapy backbones.
• Relapsed/second-line reallocation: Targeted agents and fixed-duration strategies narrowed the windows where anti-CD20 monoclonals are chosen as core therapy.
• Sequencing effects: Patients are increasingly “treated out” of later anti-CD20 options because disease biology and prior drug exposure now steer toward targeted re-treatment or alternate targeted classes.

What market dynamics have driven demand volatility?

ARZERRA demand has been influenced by three reinforcing dynamics: competitive differentiation, payer behavior, and manufacturing and commercial execution.

1) Competitive displacement from modern CLL standards

Anti-CD20 monoclonals face a market where survival outcomes increasingly correlate with targeted agent selection and combination regimens. As clinicians and payers compare regimens, oral targeted therapies tend to win formulary consideration due to convenience, administration profile, and robust outcome datasets.

Implication for ARZERRA: Anti-CD20 is increasingly a secondary or limited-choice component, not the default backbone.

2) Payer formulary and reimbursement pressure

Health plans increasingly optimize coverage around newer agents and negotiated rebates. As utilization shifts to targeted therapies, payer interest in older infusional antibodies typically declines unless a clear value proposition exists in a defined subgroup or combination protocol.

Implication for ARZERRA: The addressable market tightens through narrower preferred-access status and lower probability of first-line and broad relapsed use.

3) Patient migration and reduced eligibility windows

CLL treatment is now guided by prior therapies, comorbidity tolerance, and the expectation of long-term disease control with targeted drugs. That shifts the patient pool away from regimens that require infusion and a chemo-like treatment experience.

Implication for ARZERRA: Even when clinical use persists, the incident-use share shrinks over time.

How has the commercial trajectory evolved since launch?

ARZERRA’s commercial trajectory follows the typical pattern of a specialty biologic in a therapeutic area that rapidly changes standards of care: initial uptake, then a decline in growth rate, followed by revenue plateauing and erosion as competition intensifies and patient selection narrows.

Revenue and profitability path (directional)

• Launch and early scale-up: ARZERRA entered a market where anti-CD20-based approaches still had broader adoption.
• Middle-cycle pressure: As BTK inhibitors and BCL2 inhibitors gained share, ARZERRA faced higher scrutiny versus newer options in both frontline and relapsed settings.
• Late-cycle contraction: With continued standard-of-care evolution, ARZERRA’s revenue mix concentrated into fewer remaining use cases, limiting topline elasticity.

What do label scope and usage constraints imply for market ceiling?

Even when a biologic maintains regulatory relevance, the market ceiling depends on approved indication breadth and how practice aligns with label positioning. For ARZERRA, the indication ecosystem is narrower than the regimens that increasingly dominate CLL treatment selection.

Label-aligned adoption limits

• Infusion-based therapy tends to lose demand against oral regimens unless there is a strong clinical or economic rationale.
• Combination practices for CLL often center on therapies that anchor regimens around targeted agents rather than anti-CD20 antibodies.

What financial drivers likely mattered most to ARZERRA performance?

For a biologic like ARZERRA, financial performance is primarily driven by utilization volumes, net price (rebates and discounts), and competitive share. The market dynamics above imply the dominant drivers of ARZERRA’s trajectory.

Utilization volume: the key negative driver

• As clinician prescribing shifted to targeted oral therapies, prescription volume for anti-CD20 options decreased.
• Remaining usage clustered into specific settings, which reduces total addressable demand.

Net price: secondary but persistent compression

• Payer leverage increases when a product loses preferred status.
• Competitive pressure tends to lift rebate intensity even when list price remains stable.

Mix effects and cohort aging

• CLL prevalence continues to rise, but treatment is increasingly spread across more lines and more targeted options, which can dilute the share of any one therapy class.

How does competitive intensity shape ARZERRA’s near-term outlook?

Near-term outlook is constrained by the current CLL competitive landscape. ARZERRA competes in a class (anti-CD20 monoclonals) that no longer anchors standard-of-care decisions in broad patient segments. Unless new evidence expands ARZERRA’s role into earlier lines or higher-value combinations, its market position remains structurally limited.

Likely market outcomes

• Share stability at best in narrow segments rather than broad resurgence.
• Ongoing pricing and access pressure as newer agents remain preferred.
• Incremental demand tied to practice patterns rather than major category growth.

Key business impact: what should investors and R&D teams infer?

ARZERRA illustrates a standard pattern in mature oncology immunotherapy classes: once targeted regimens take over the dominant lines, biologics face a longer-tail demand curve with limited upside absent strong new clinical differentiation.

Business conclusions

• Commercial durability depends on line-of-therapy dominance, not solely on label presence.
• Payer preference follows outcome-and-practicality comparisons, which increasingly favor oral targeted regimens.
• Value demonstration must translate into formulary position, not only clinical endpoints.

---

Key Takeaways

• ARZERRA’s market dynamics are defined by CLL’s shift from immunochemotherapy and anti-CD20 dependence toward targeted oral regimens.
• Competitive displacement compresses utilization volume and tightens the patient segments where anti-CD20 remains a common choice.
• The financial trajectory aligns with shrinking addressable demand, payer pressure, and constrained late-cycle growth.

---

FAQs

1) What drove ARZERRA’s market shrinkage?
Shift in CLL standard of care toward BTK inhibitors and BCL2-pathway therapies reduced the share of patients treated with anti-CD20-based regimens.

2) Does ARZERRA have broad frontline demand?
Frontline demand is structurally constrained because modern CLL treatment standards prioritize targeted regimens.

3) Is payer pressure the main financial factor?
Utilization volume changes dominate; payer pressure accelerates the impact through formulary access and net-price compression.

4) Can ARZERRA regain meaningful growth?
Growth would require a clear expansion into higher-volume lines or combinations that earn preferred access under current practice.

5) What does ARZERRA imply for similar biologics in mature oncology?
A product’s long-term ceiling depends on sustaining a central role in therapy sequencing, not just having an active label.

---

References (APA)

[1] FDA. (n.d.). ARZERRA (ofatumumab) Prescribing Information. U.S. Food and Drug Administration.
[2] National Cancer Institute. (n.d.). Chronic Lymphocytic Leukemia Treatment (PDQ) summaries. U.S. National Institutes of Health.
[3] EMA. (n.d.). Arzerra (ofatumumab): Product information. European Medicines Agency.